论文信息 - A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort - 字舞流文

A prospective observational post‐marketing study of natalizumab‐treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

BIONAT is a French multicentric phase IV study of natalizumab (NTZ)‐treated relapsing−remitting multiple sclerosis (MS) patients. The purpose of this study was to collect clinical, radiological and biological data on 1204 patients starting NTZ, and to evaluate the clinical/radiological response to NTZ after 2 years of treatment.

P. Vermersch | M. Clanet | B. Brochet | E. Thouvenot | P. Cabre | L. Rumbach | D. Brassat | W. Camu | D. Laplaud | B. Fontaine | G. Defer | A. Fromont | M. Debouverie | T. Moreau | J. Pelletier | A. Tourbah | C. Lubetzki | P. Clavelou | P. Labauge | A. Rico | H. Zéphir | C. Papeix | M. Cohen | O. Outteryck | S. Wiertlewski | J. Ouallet | C. Lebrun-Frénay | E. Berger | G. Castelnovo | P. Hautecoeur | O. Casez | N. Derache | J. Seze | J. Ongagna | Thibault Moreau | S. Pittion | N. Couturier | N. Bohossian | Bruno Brochet | Gilles Defer | Nicolas Couturier | M. Clanet | P. Vermersch | Lucien Rumbach | P. Cabre | Mikael Cohen | P. Labauge

[1] G. Comi,et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort , 2013, Multiple sclerosis.

[2] C. Pozzilli,et al. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis , 2012, Journal of the Neurological Sciences.

[3] A. Damasceno,et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients , 2012, Multiple sclerosis.

[4] A. Svenningsson,et al. Humoral immune response to influenza vaccine in natalizumab-treated MS patients , 2012, Neurological research.

[5] H. Wiendl,et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort , 2012, Neurology.

[6] Meena Subramanyam,et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[7] J. Chapman,et al. Epidemiology of Anti-JCV Antibodies in Israeli Multiple Sclerosis Population (P02.138) , 2012 .

[8] P. Vermersch,et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy , 2012, Journal of Neurology.

[9] G. Izquierdo,et al. Immunological markers of optimal response to natalizumab in multiple sclerosis. , 2012, Archives of neurology.

[10] A. Sandrock,et al. Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1 , 2011, Annals of neurology.

[11] D. Bates,et al. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity , 2011, Journal of Neurology, Neurosurgery & Psychiatry.

[12] E. de Ramón,et al. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study , 2011, Multiple sclerosis.

[13] P. Vermersch,et al. B-cell subsets up-regulate α4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset , 2011, Neuroscience Letters.

[14] G. Comi,et al. Freedom from disease activity in multiple sclerosis , 2010, Neurology.

[15] M. Edström,et al. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid , 2010, Multiple Sclerosis.

[16] P. Vermersch,et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice , 2010, Journal of Neurology.

[17] Adrian Egli,et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. , 2009, The Journal of infectious diseases.

[18] C. Polman,et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.

[19] M. Krumbholz,et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis , 2008, Neurology.

[20] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[21] X. Montalban,et al. Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients , 2006, Annals of neurology.

[22] G. Comi,et al. Three years of experience: the Italian registry and safety data update , 2010, Neurological Sciences.

[23] F. Piehl,et al. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study , 2010, Neurological Sciences.

[24] C. Pozzilli,et al. Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome , 2010, Neurological Sciences.

[25] L. Kappos,et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL , 2009, Journal of Neurology.

[26] A. Verma. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL , 2008 .